Wolfgang Wick MDProf. Dr. Med. Wolfgang Wick, Chairman, Neurology Clinic, University of Heidelberg, Heidelberg, Germany
Dr. Wolfgang Wick, is Division Head of Neuro-Oncology at the German Cancer Research Center (DKFZ), Program Chair of Neuro-Oncology at the National Center for Tumor Diseases (NCT), and Professor of Neurology and Chairman at the Neurology Clinic in Heidelberg, Germany.
He received training in neurology at the University of Tübingen Medical School Department of Neurology in Tübingen, Germany, then at medical schools at the University of Bonn (Germany), King’s College in London (UK), and Harvard Medical School, Boston, Massachusetts (USA).
He is currently conducting multicenter phase I–III randomized trials for the Neurooncology Working Group (NOA) of the German Cancer Society, the European Organisation for Research and Treatment of Cancer (EORTC), the EU GAPVAC consortium, as well as a number of multicenter trials with the pharmaceutical industry. He is a steering committee member of the European Association for Neurooncology, and the EORTC Brain Tumor Group, which he chaired for over 6 years. Currently he is chair of the NOA.
Dr. Wick’s main scientific interests include resistance mechanisms, immunotherapy, biomarkers, and radiosensitization. He has written almost 300 publications in peer-reviewed journals, such as the Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Nature, Nature Medicine, Neurology, Neuro Oncology, Annals of Neurology, The New England Journal of Medicine, and Journal of Clinical Investigation.
Recent Contributions to PracticeUpdate:
- ASCO 2017: Emerging Data on Therapies for Gliomas
- A Comparison of PCV and Temozolomide: Clinical Perspectives and a Review of Data
- Current Status of Vaccines and Immunotherapy in High Grade Gliomas: An Update from SNO 2016
- Clinical Implications of New Molecular Understanding in Glioblastoma
- Personalized Medicine in Neuro-Oncology
- EORTC Trial Results: Combining Bevacizumab With Lomustine